Combination Immunotherapy Improves Outcomes for BCG Unresponsive Non Muscle Invasive Bladder Cancer
Combination immunotherapy shows promise for bladder cancer patients
Multi-agent immunotherapy regimens show superior response rates and progression-free survival compared to monotherapy in patients with NMIBC…
A new combination of immunotherapies may improve response rates and survival for patients with specific types of bladder cancer.
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
47 late-phase programs aim to improve PD-1/PD-L1 cancer therapies
This narrative review analyzes registry-derived clinical trial data to identify future directions for PD-1 and PD-L1 inhibitor therapies. Th…
A new review maps 47 late-phase programs working to overcome limits of PD-1/PD-L1 cancer treatments through 2030.
PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
Adding PD-1 inhibitors to chemotherapy improves lung cancer survival
This network meta-analysis of 20 randomized controlled trials evaluated treatments for driver gene-negative non-small cell lung cancer with …
Combining a specific immunotherapy drug with chemotherapy may help patients with certain types of lung cancer and liver spread live longer.
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
Multi-Omic Biomarkers May Improve Lung Cancer Treatment Predictions
This narrative review explores the integration of chemokine signatures and multi-omic biomarkers to predict immune checkpoint inhibitor resp…
New research suggests that combining multiple biological markers can better predict how lung cancer patients will respond to immunotherapy.
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
Systematic review of immune checkpoint inhibitors in cancer efficacy and safety
Immune Checkpoint Inhibitors Show Promise For Cancer Patients With High Tumor Burden
This systematic review synthesizes evidence from 15 randomized trials and cohort studies on immune checkpoint inhibitors in cancer. It finds…
A review of trials suggests immune checkpoint inhibitors work well for some cancer patients but carry risks like skin rashes and organ infla…
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
New Drug Combo Shows Strong Results for Advanced Bladder Cancer
This retrospective cohort study evaluated disitamab vedotin combined with a PD-1 inhibitor in 132 patients with locally advanced or metastat…
A new drug pairing shrank tumors in 71% of advanced bladder cancer patients, even those with diabetes or kidney problems.
All PD-1 inhibitors Articles
- Combination Immunotherapy Improves Outcomes for BCG Unresponsive Non Muscle Invasive Bladder Cancer
- High tumor mutational burden correlates with improved objective response rate in HNSCC patients
- Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
- PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
- Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
- Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
- PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
- Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
- PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
- Systematic review of immune checkpoint inhibitors in cancer efficacy and safety
- Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
- Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
- HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Narrative review discusses immune checkpoint inhibitors in lung cancer patients
- Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
- Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors